NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03428100,A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable,https://clinicaltrials.gov/study/NCT03428100,BREEZE-AD4,COMPLETED,"The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine or are intolerant to, or have contraindication to cyclosporine.",YES,Atopic Dermatitis,DRUG: Baricitinib|DRUG: Placebo|DRUG: Topical corticosteroid,"Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib), The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score., Week 16","Percentage of Participants Achieving EASI75 (Placebo, 1 mg Baricitinib), The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.

Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who permanently discontinue, are rescued, or are without at least 1 post-baseline observation., Week 16|Percentage of Participants Achieving IGA of 0 or 1 With a ≥ 2 Point Improvement, The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification., Week 16|Percentage of Participants Achieving EASI90, The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI90 is defined as a ≥ 90% improvement from baseline in the EASI score., Week 16|Percent Change From Baseline in EASI Score, The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease).

Least Squares Mean (LSM) were calculated using mixed model repeated measures (MMRM) model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline score and baseline score-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75), The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease.

The SCORAD75 responder is defined as a participant who achieves a ≥ 75% improvement from baseline in the SCORAD score., Week 16|Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS), The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing ""no itch"" and 10 representing ""worst itch imaginable."" Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours., Week 16|Change From Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS), The ADSS is a 3-item, participant-administered questionnaire developed to assess the impact of itch on sleep including difficulty falling asleep due to itch, frequency of waking due to itch, and difficulty getting back to sleep last night due to itch. Item 2 frequency of waking last night is reported by selecting the number of times they woke up each night, ranging from 0 to 29 times, where the higher a number indicates a worse outcome. The ADSS is designed to be completed daily, using a daily diary, with respondents thinking about sleep ""last night."" Each item is scored individually.

LS Mean were calculated using an MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical and baseline and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Change From Baseline in Skin Pain NRS, Skin Pain NRS is a participant-administered,11-point horizontal scale anchored at 0 and 10, with 0 representing ""no pain"" and 10 representing ""worst pain imaginable."" Overall severity of a participant's skin pain is indicated by selecting the number, using a daily diary, that best describes the worst level of skin pain in the past 24 hours.

LS Mean were calculated using MMRM model includes treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Percentage of Participants Achieving IGA of 0 or 1 With a >=2-point Improvement, The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification., Week 24|Percentage of Participants Achieving EASI50, The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI50 is defined as a ≥ 50% improvement from baseline in the EASI score., Week 16|Percentage of Participants Achieving EASI75, The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score., Week 24|Percentage of Participants Achieving IGA of 0, The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification., Week 16|Change From Baseline in SCORAD, The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with VAS where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease.

LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Percentage of Participants Achieving SCORAD90, The SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3)oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with a visual analogue scales (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. The SCORAD90 responder is defined as a participant who achieves a ≥ 90% improvement from baseline in the SCORAD score., Week 16|Change From Baseline in Body Surface Area (BSA) Affected, The BSA affected by AD will be assessed for 4 separate body regions and is collected as part of the EASI assessment: head and neck, trunk (including genital region), upper extremities, and lower extremities (including the buttocks). Each body region will be assessed for disease extent ranging from 0% to 100% involvement. The overall total percentage will be reported based off of all 4 body regions combined, after applying specific multipliers to the different body regions to account for the percent of the total BSA represented by each of the 4 regions. Use the percentage of skin affected for each region (0 to 100%) in EASI as follows: BSA Total = 0.1\*BSAhead and neck + 0.3\*BSAtrunk + 0.2\* BSAupper limbs + 0.4\*BSAlower limbs.

LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment, Percentage of participants developing skin infections requiring antibiotic treatment., Week 16|Mean Number of Days Without Topical Corticosteroids (TCS) Use, The ANCOVA model includes treatment, region, and baseline disease severity (IGA) as factors., Week 16|Mean Gram Quantity of Low and Moderate Potency Background Topical Corticosteroid (TCS) Used (Tube Weights), Average weights of full tubes were used to determine the dispensed weights for each region. Returned tubes were weighed with cap without carton to determine the amount of TCS in grams (g) used at each visit. Analysis was done via analysis of variance (ANOVA), with geographic region, baseline disease severity, and treatment as factors in the model., Week 16|Percent Change From Baseline in Itch NRS, The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing ""no itch"" and 10 representing ""worst itch imaginable."" Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects., Baseline, Week 16|Percent Change From Baseline in Itch NRS at Week 24, The Itch NRS is a participant-administered, 11-point horizontal scale, with 0 representing ""no itch"" and 10 representing ""worst itch imaginable."" Overall severity of a participant's itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours.

LS Means were calculated using MMRM model with treatment, region, baseline disease severity, visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-interaction as fixed continuous effects., Baseline, Week 24|Change From Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM), The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) on a scale ranging from 0-4 (0 = no days, 1 = 1-2 days, 2 = 3-4 days, 3 = 5-6 days, 4 = everyday). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). High scores are indicative of more severe disease and poor quality of life.

LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by visit-interactions as fixed continuous effects., Baseline, Week 16|Change From Baseline in the Patient Global Impression of Severity - Atopic Dermatitis (PGI-S-AD) Score, The PGI-S-AD is a single-item question asking the participant how they would rate their overall AD symptoms over the past 24 hours, using a daily diary. The 5 categories of responses are ""(0) no symptoms"", ""(1) very mild"", ""(2) mild"" ""(3) moderate"", and ""(4) severe.""

LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Change From Baseline on the Hospital Anxiety Depression Scale (HADS), The HADS is a participant-rated instrument used to assess both anxiety and depression. This instrument consists of 14 item questionnaire, each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.'

LS Mean were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Change From Baseline in the Dermatology Life Quality Index (DLQI), The DLQI is a simple, participant-administered,10 question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last ""week."" Response categories include ""not at all,"" ""a little,"" ""a lot,"" and ""very much,"" with corresponding scores of 0, 1, 2, and 3, respectively, and unanswered or ""not relevant"" responses scored as ""0."" Scores range from 0 to 30 (""no impact on participant's life"" to ""extremely large effect on participant's life""), and a 4-point change from baseline is considered as the minimal clinically important difference threshold.

LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Change From Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire, The WPAI-AD participant questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. The WPAI-AD consists of 6 items grouped in 4 domains: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment.

LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Change From Baseline in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Index Score United States and United Kingdom Algorithm, The EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1, with higher score indicating better health state.

LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interaction as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16|Change From Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Visual Analog Score (VAS), EQ-5D-5L is a 2-part measurement. The second part is assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.

LS Means were calculated using MMRM model with treatment, region, baseline disease severity (IGA), visit, and treatment-by-visit-interactions as fixed categorical effects and baseline and baseline-by-visit-interaction as fixed continuous effects., Baseline, Week 16",,Eli Lilly and Company,Incyte Corporation,ALL,"ADULT, OLDER_ADULT",PHASE3,463,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",16841|I4V-MC-JAIN|2017-004574-34,2018-05-15,2019-11-25,2023-04-20,2018-02-09,2020-11-26,2023-05-23,"Universitätsklinikum Graz, Graz, Steiermark, 8036, Austria|Universitätsklinik Innsbruck, Innsbruck, Tyrol, 6020, Austria|KA Rudolfstiftung, Wien, 1030, Austria|AKH, Wien, 1090, Austria|Sozialmed. Zentrum Ost - Donauspital, Wien, 1220, Austria|Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium|Universitair Ziekenhuis Brussel, Brussel, 1090, Belgium|Universitair Ziekenhuis Gent, Gent, 9000, Belgium|UZ Leuven - Campus Sint-Rafaël, Leuven, 3000, Belgium|Cedoes Centro Diagnostico Pequisa Osteoporose E Santo Ltd, Vitoria, ES, 29055 450, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90020-090, Brazil|Hospital Moinhos de Vento - Instituto de Educação e Pesquisa, Porto Alegre, Rio Grande Do Sul, 90560-030, Brazil|CCBR Brasil Centro de Analises e Pesquisas Clínicas LTDA, Rio de Janeiro, RJ, 22271-100, Brazil|IDERJ - Instituto de Dermatologia e Estética do Brasil, Rio de Janeiro, RJ, 22470-220, Brazil|Faculdade de Ciências Médicas - UNICAMP, Campinas, Sao Paulo, 13083-887, Brazil|Fundação Faculdade de Medicina do ABC, Santo André, Sao Paulo, 09060-650, Brazil|Hospital das Clinicas da FMRP, Ribeirao Preto, SP, 14048-900, Brazil|Hospital da Clinicas da Faculdade de Medicina da USP, Sao Paulo, 05403-000, Brazil|Terveystalo Tampere, Tampere, Irkanmaa, 33100, Finland|Helsinki University Central Hospital, Helsinki, 00250, Finland|Hospital Mehiläinen Neo, Turku, 20520, Finland|Hôpital de Pontchaillou, Rennes, Cedex 9, 35033, France|CHU de Besancon Hopital Jean Minjoz, Besancon Cedex, 25030, France|CHU de Bordeaux Hopital Saint Andre, Bordeaux Cedex, 33075, France|Hôpital C. HURIEZ, Lille, 59037, France|Hôpital Emile Muller, Mulhouse, 68100, France|Chru De Nantes Hotel-Dieu, Nantes Cedex 1, 44093, France|CHU de Nice Hopital de L'Archet, Nice cedex 3, 06202, France|Hopital Sainte Anne (H.I.A), Toulon Cedex 9, 83800, France|Hopital Larrey, Toulouse cedex 9, 31059, France|Centre Hospitalier de Valence, Valence, 26953, France|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, 69120, Germany|Hautarztpraxis Dr. Leitz und Kollegen, Stuttgart, Baden-Württemberg, 70178, Germany|Universitätsklinikum Erlangen, Erlangen, Bayern, 91054, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, 80802, Germany|Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt am Main, Hessen, 60590, Germany|Elbe Kliniken Stade Buxtehude GmbH Klinikum Buxtehude, Buxtehude, Niedersachsen, 21614, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, 30449, Germany|Klinische Forschung Osnabrück, Osnabrück, Niedersachsen, 49074, Germany|Fachklinik Bad Bentheim, Bad Bentheim, Nordrhein-Westfalen, 48455, Germany|St Josef-Hospital Bochum, Bochum, Nordrhein-Westfalen, 44791, Germany|Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen, 53127, Germany|Universitaetsklinikum Essen, Essen, Nordrhein-Westfalen, 45147, Germany|Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, 48149, Germany|Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Rheinland-Pfalz, 55131, Germany|Universitätsklinikum Jena, Jena, Thüringen, 07743, Germany|Charité Universitätsmedizin Berlin, Berlin, 10117, Germany|Universitätsklinikum Hamburg - Eppendorf, Hamburg, 20246, Germany|Fondazione IRCCS Osp.Maggiore Policlinico - Dermatologia, Milano, Milan, 20122, Italy|Ospedale Clinicizzato San Donato, San Donato Milanese, Milan, 20097, Italy|Dip.to Med. Sperimentale -Polic.Umberto I -Univ. La Sapienza, Roma, Rome, 00161, Italy|Azienda Ospedaliera Umberto I, Ancona, 60020, Italy|Spedali Civili - Universita degli Studi, Brescia, 25123, Italy|Fondazione Universitaria degli Studi G D'Annunzio, Chieti, 66100, Italy|Azienda Ospedaliera di Perugia, Perugia, 06129, Italy|Arcispedale Santa Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, 42123, Italy|Policlinico di Tor Vergata, Roma, 00133, Italy|Ospedale Policlinico Giambattista Rossi, Borgo Roma, Verona, 37134, Italy|Yanagihara dermatology clinic, Ainokawa, Ichikawa-shi, Chiba, 272-0143, Japan|Fumimori Clinic, Fukuoka-shi, Fukuoka, 815-0082, Japan|Queen's Square Dermatology and Allergology, Nishi-ku, Yokohama-city, Kanagawa, 220-6208, Japan|Noguchi Dermatology, Kashima-machi, Kamimashiki-gun, Kumamoto, 861-3101, Japan|Yoshioka Dermatology Clinic, Neyagawa-shi, Osaka, 572-0838, Japan|Kume Clinic, Nishi-ku Sakai-shi, Osaka, 593-8324, Japan|Sanrui Dermatology Clinic, Ohmiya-ku,Saitama-shi, Saitama, 330-0854, Japan|Iidabashi Clinic, Chiyoda-ku, Tokyo, 102-0072, Japan|Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, 103-0025, Japan|Sumire Dermatology Clinic, Edogawa-ku, Tokyo, 133-0057, Japan|Tachikawa Dermatology Clinic, Tachikawa-shi, Tokyo, 190-0023, Japan|Academisch Medisch Centrum, Amsterdam, 1105 AZ, Netherlands|Bravis Ziekenhuis, Bergen op Zoom, 4624 VT, Netherlands|Amphia Ziekenhuis, Breda, 4818 CK, Netherlands|NZOZ Specjalistyczna Przychodnia Dermatologiczna Specderm, Bialystok, 15-375, Poland|Centrum Badan Klinicznych, PI House, Gdansk, 80-546, Poland|Centrum Medyczne Angelius Provita, Katowice, 40-611, Poland|Barbara Rewerska DIAMOND CLINIC, Krakow, 31-559, Poland|Dermed Centrum Medyczne Sp. z o.o., Lodz, 90-265, Poland|Miejski Szpital Zespolony w Olsztynie Klinika Dermatologii, Olsztyn, 10-229, Poland|DermoDent, Centrum Medyczne Czajkowscy, Osielsko, 86-031, Poland|LASER CLINIC Specjalistyczne Gabinety Lekarskie, Szczecin, 70-332, Poland|Wojskowy Instytut Medyczny CSK MON, Warsaw, 04-141, Poland|Centralny Szpital Kliniczny MSW Klinika Dermatologii, Warszawa, 02-507, Poland|State scientific centre for dermatovenerology and cosmetolog, Moscow, 107076, Russian Federation|First Moscow State Medical University n.a. Sechenov, Moscow, 119991, Russian Federation|LLC ArsVitae NorthWest, Saint-Petersburg, 194223, Russian Federation|LLC Medical Center ""Kurator"", Saint-Petersburg, 196240, Russian Federation|SPb SBHI Skin-venerologic dispensary #10, St. Petersburg, 194021, Russian Federation|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital Univ. Puerta de Hierro, Majadahonda, Madrid, 28220, Spain|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, 28223, Spain|Hospital Universitario de Torrejon, Torrejón de Ardoz, Madrid, 28850, Spain|Hospital de Manises, Manises, Valencia, 46940, Spain|Hospital De Basurto, Bilbao, Vizcaya, 48013, Spain|Hospital Universitario Dr Pesset, Valencia, 46017, Spain|Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, 9007, Switzerland|Inselspital Bern, Bern, 3010, Switzerland|Universitätsspital Zürich, Zürich, 8091, Switzerland|Salford Royal NHS Foundation Trust, Salford, Greater Manchester, M6 8HD, United Kingdom|West Glasgow Ambulatory Care Hospital, Glasgow, Lanarkshire, G3 8SJ, United Kingdom|Whipps Cross University Hospital, Leytonstone, London, E11 1NR, United Kingdom|Broadgreen Hospital, Liverpool, Merseyside, L14 3LB, United Kingdom|Guys/St. Thomas Hospital, London, Surrey, SE1 9RT, United Kingdom|The Dudley Group NHS Foundation Trust, Dudley, West Midlands, DY1 2HQ, United Kingdom","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/00/NCT03428100/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/00/NCT03428100/SAP_001.pdf"
